STOCK TITAN

Theratechnologies Inc. - THTX STOCK NEWS

Welcome to our dedicated news page for Theratechnologies (Ticker: THTX), a resource for investors and traders seeking the latest updates and insights on Theratechnologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Theratechnologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Theratechnologies's position in the market.

Rhea-AI Summary
Theratechnologies mails its 2024 management proxy circular to shareholders for the upcoming annual meeting, announcing the retirement of Gérald Lacoste and the appointment of Frank Holler as Chair of the Board.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
none
-
Rhea-AI Summary
Theratechnologies Inc. announced that its President and CEO will be presenting at the 2024 Bloom Burton & Co. Healthcare Investor Conference in Toronto. The conference will take place on April 16-17, with the presentation scheduled for April 17 at 10:00 AM ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
conferences
-
Rhea-AI Summary
Theratechnologies Inc. reported Q1 2024 revenue of $16.2 million, marking the third consecutive quarter of near-flat-to-positive Adjusted EBITDA. FY2024 revenue guidance is confirmed between $87-$90 million with Adjusted EBITDA of $13-15 million. The Phase 1 trial of sudocetaxel zendusortide in advanced ovarian cancer is accelerating. Recent business highlights include the completion of enrollment for Phase 1 trial participants and the appointment of new Board members. Financially, there was an 18.4% decrease in revenue compared to the previous year, with EGRIFTA SV® and Trogarzo® sales declining. Despite lower revenues, the net loss improved to $4.4 million from $10.4 million in Q1 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.9%
Tags
Rhea-AI Summary
Theratechnologies Inc. presented preclinical data at the AACR annual meeting highlighting the significant tumor regression in colorectal cancer and triple-negative breast cancer xenograft models using investigational camptothecin-peptide conjugates. The study also showed synergistic anti-tumor efficacy with combination therapy. The SORT1+ Technology™ platform utilizes a novel peptide to target SORT1 for receptor-mediated internalization of anticancer agents. The platform demonstrated promising tolerability and anti-tumor effects, supporting its potential in developing novel peptide-drug conjugates for various cancer types.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.21%
Tags
-
Rhea-AI Summary
Theratechnologies Inc. appoints Elina Tea, Chief Financial Officer at GLS North America, to its Board of Directors and Audit Committee. Ms. Tea's extensive financial and business development experience brings valuable insights to the Company as it focuses on commercial business and new partnerships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.67%
Tags
management
-
Rhea-AI Summary
Theratechnologies Inc. will report financial results and provide a business update for its first quarter on April 10, 2024. The call will be hosted by CEO Paul Lévesque and other key members of the management team.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
Rhea-AI Summary
Theratechnologies Inc. announces the presentation of two posters at the AACR Annual Meeting 2024, showcasing the potential of their SORT1+ Technology™ platform for treating colorectal cancers. The studies demonstrate the effectiveness of sudocetaxel zendusortide (TH1902) in activating anti-PD-L1 immunotherapy tumor cell killing and introduce new camptothecin-peptide conjugates for SORT1+ colorectal cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.7%
Tags
conferences clinical trial
-
Rhea-AI Summary
Theratechnologies Inc. announced a shift towards a commercial focus by phasing down preclinical oncology research activities to prioritize the Phase 1 clinical trial of sudocetaxel zendusortide. The company aims to attract an oncology R&D partner leveraging its SORT1+ Technology platform. Theratechnologies also shared preclinical data at the AACR annual meeting and initiated the next cohort of patients in the Phase 1 trial. The restructuring will incur cash and non-cash charges to optimize the organizational cost structure.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
none
-
Rhea-AI Summary
Theratechnologies Inc. appoints Jordan Zwick, Chief Business Officer at Mirador Therapeutics Inc., to its Board of Directors and Audit Committee. Mr. Zwick brings extensive experience in the biotech and pharmaceutical industry, global finance, and corporate strategy to guide Theratechnologies towards profitability and growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
management
Rhea-AI Summary
Theratechnologies Inc. announces progression to next dose level in Phase 1 clinical trial for sudocetaxel zendusortide in advanced ovarian cancer patients, with positive safety outcomes and enrollment of first patient in second cohort.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
Theratechnologies Inc.

Nasdaq:THTX

THTX Rankings

THTX Stock Data

65.29M
34.20M
6.29%
50.89%
0.03%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
Montreal

About THTX

theratechnologies inc., a biopharmaceutical company, markets prescription products in the united states, europe, and canada. it offers egrifta and egrifta sv, for the reduction of excess abdominal fat in human immunodeficiency virus (hiv)-infected patients with lipodystrophy; and trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant hiv-1 infected patients. the company's pipeline products include f8 formulation that could be used for the treatment of hiv-associated lipodystrophy; th-1902 for the treatment of triple negative breast cancer; and th-1904 for the treatment of ovarian cancer. the company was founded in 1993 and is headquartered in montreal, canada.